Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
- PMID: 28041972
- DOI: 10.1016/j.humpath.2016.12.019
Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Abstract
In patients treated with neoadjuvant chemotherapy (NAC), there is no consensus on retesting biomarkers within the excision specimen. Our aim was to investigate the clinical relevance of biomarker changes post-NAC at a large tertiary medical center. A retrospective search was performed to identify cases from 2012 to 2015 with needle biopsy-confirmed invasive breast carcinoma treated with NAC and subsequent excision containing residual invasive tumor. Biomarkers (estrogen receptor [ER], progesterone receptor [PR], and HER2/neu [HER2]) were performed on all pre-NAC biopsies. One hundred fifty-four NAC-treated cases were identified in which 83 (54%) had repeat testing of at least 1 biomarker on the surgical specimen. Twenty-five (30%) of 83 repeated cases demonstrated changes in pre-NAC biopsy versus post-NAC resection biomarker status. There was no impact of age or grade on biomarker status changes. Tumors that were triple negative at biopsy were more likely to remain triple negative. Clinically relevant changes were identified including the following: (1) ER negative to ER positive, 2 (3%) of 75; (2) PR negative to PR positive with ER negative both pre- and post-NAC, 2 (3%) of 73; and (3) HER2 negative to positive, 1 (1%) of 77. Four of 5 of the changes led to modifications of the adjuvant treatment regimen, including the addition of adjuvant tamoxifen, anastrazole, or trastuzumab. In summary, post-NAC biomarker repeat testing in patients with breast cancer impacts therapeutic management in a small subset of patients and therefore, repeat testing may be considered for patients that are hormone receptor and/or HER2 negative before NAC.
Keywords: Biomarker; Breast cancer; ER; HER2; Neoadjuvant; PR; Repeat testing.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment in
-
HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?-reply.Hum Pathol. 2017 Jul;65:247-248. doi: 10.1016/j.humpath.2017.02.026. Epub 2017 Apr 22. Hum Pathol. 2017. PMID: 28438618 No abstract available.
-
HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?Hum Pathol. 2017 Jul;65:247. doi: 10.1016/j.humpath.2017.02.025. Epub 2017 Apr 21. Hum Pathol. 2017. PMID: 28438621 No abstract available.
Similar articles
-
Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.J BUON. 2017 May-Jun;22(2):638-643. J BUON. 2017. PMID: 28730768
-
Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.Hum Pathol. 2017 Jul;65:123-132. doi: 10.1016/j.humpath.2017.04.016. Epub 2017 Apr 27. Hum Pathol. 2017. PMID: 28457730
-
Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25400769 Free PMC article.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
-
Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.Arch Pathol Lab Med. 2019 Dec;143(12):1444-1449. doi: 10.5858/arpa.2019-0205-RA. Epub 2019 Aug 2. Arch Pathol Lab Med. 2019. PMID: 31373514 Review.
Cited by
-
Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.Diagn Pathol. 2024 Mar 20;19(1):53. doi: 10.1186/s13000-024-01451-y. Diagn Pathol. 2024. PMID: 38509525 Free PMC article.
-
Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress.Front Oncol. 2023 Oct 3;13:1169010. doi: 10.3389/fonc.2023.1169010. eCollection 2023. Front Oncol. 2023. PMID: 37854685 Free PMC article. Review.
-
Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.Clin Transl Oncol. 2024 Apr;26(4):880-890. doi: 10.1007/s12094-023-03318-y. Epub 2023 Sep 13. Clin Transl Oncol. 2024. PMID: 37702827
-
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.Breast Cancer Res Treat. 2023 Jul;200(2):247-256. doi: 10.1007/s10549-023-06978-0. Epub 2023 May 26. Breast Cancer Res Treat. 2023. PMID: 37233961 Free PMC article.
-
Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers.Cell Rep Med. 2023 Mar 21;4(3):100977. doi: 10.1016/j.xcrm.2023.100977. Epub 2023 Mar 14. Cell Rep Med. 2023. PMID: 36921599 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous